Targeted Oncology presents Precision Medicine, a video series featuring oncology experts discussing how to use a more customized approach when treating patients with cancer.
The Evolving Treatment Paradigm for Patients with KRASG12C Mutated NSCLC and CNS MetastasesDecember 20th 2022
Mark Socinski, MD, and Joshua Sabari, MD, discuss the treatment options for patients with KRASG12C mutated NSCLC with CNS metastases, and share advice for community oncologists treating this population.
Potential Role of Magrolimab in the Treatment of Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)September 29th 2022
Hetty Carraway, MD, and Eytan M. Stein, MD, discuss treatment options for patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, and how to select the best treatment regimen based on patient and disease factors.
Bruton’s Tyrosine Kinase in B-Cell Malignancies: Advances in Targeted TherapySeptember 30th 2021
Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss and compare BTK inhibitors used as targeted therapy for B-cell malignancies, taking into account data from clinical trials and their personal experiences.
Selective Immunomodulating Microtubule Binding Agents (SIMBA): A Novel Approach To Chemotherapy-Induced NeutropeniaSeptember 2nd 2021
Future implications for palliative therapy with selective immunomodulating microtubule binding agents as prevention against chemotherapy-induced neutropenia in high-risk patients with solid tumors.
EGFR Exon 20 Insertion as a Therapeutic Target in Non-small Cell Lung CancerAugust 12th 2021
Joel Neal, MD, PhD, and Alexander I. Spira, MD, PhD, FACP, talk about the role of EGFR, particularly exon 20 insertion, in NSCLC growth and progression, and review the mechanism of action and current safety and efficacy data from the mobocertinib trial.
Targeting PSMA in Advanced Prostate CancerMarch 30th 2021
Experts in genitourinary oncology discuss emerging research surrounding the clinical utility of phenotypic biomarkers, such as prostate-specific membrane antigen (PSMA), for use in the treatment of metastatic castration-resistant prostate cancer.
Advancing Survival in Relapsed/Refractory Multiple MyelomaJuly 28th 2020
A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.
Expanding Options for Relapsed/Refractory Gastrointestinal Stromal TumorsJuly 1st 2020
Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.